Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.49 |
| ▸ | PPARG | P37231 | 9/20 | 0.49 |
| ▸ | PPARD | Q03181 | 12/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657163 | 1.00 | PPARA (0.49) | PPARAPPARGPPARDSMN1; SMN2MRGPRX4 | |
| SCHEMBL3031946 | 0.89 | PPARD (0.54) | PPARAPPARGPPARDSMN1; SMN2 | |
| SCHEMBL3031949 | 0.89 | PPARD (0.54) | PPARAPPARGPPARDSMN1; SMN2 | |
| SCHEMBL3027851 | 0.87 | PPARD (0.47) | PPARAPPARD | |
| SCHEMBL3027855 | 0.87 | PPARD (0.47) | PPARAPPARD | |
| SCHEMBL3027857 | 0.87 | PPARD (0.47) | PPARAPPARD | |
| SCHEMBL3030250 | 0.83 | PPARA (0.45) | PPARAPPARGPPARDSMN1; SMN2 | |
| SCHEMBL3030246 | 0.83 | PPARA (0.45) | PPARAPPARGPPARDSMN1; SMN2 | |
| SCHEMBL655681 | 0.83 | PPARA (0.44) | PPARAPPARGPPARDSMN1; SMN2 | |
| SCHEMBL3034484 | 0.82 | PPARA (0.43) | PPARAPPARGPPARDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
| US-20120046350-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.